Key Highlights:
- Alnylam Pharmaceuticals and Halozyme Therapeutics receive positive feedback from European regulators.
- Wall Street analysts predict a 25.32% upside for Alnylam's stock price.
- GuruFocus estimates a potential 72.26% upside for Alnylam, indicating significant growth potential.
Alnylam Pharmaceuticals (ALNY, Financial) and Halozyme Therapeutics (HALO) have both secured positive endorsements from the European Medicines Agency's advisory committee. Alnylam's promising drug, vutrisiran, is on the verge of approval for the treatment of transthyretin amyloidosis in cardiomyopathy. Meanwhile, Halozyme's Vyvgart, in conjunction with Enhanze, is aimed at combating chronic inflammatory demyelinating polyneuropathy.
Wall Street Analysts Forecast
According to the combined insights of 28 analysts, Alnylam Pharmaceuticals Inc (ALNY, Financial) boasts an average target price of $317.82. This projection includes a high estimate of $500.00 and a low estimate of $195.00, implying a potential upside of 25.32% from its current stock price of $253.60. For a more in-depth analysis, visit the Alnylam Pharmaceuticals Inc (ALNY) Forecast page.
Additionally, when examining the consensus recommendation from 33 brokerage firms, Alnylam Pharmaceuticals Inc (ALNY, Financial) is rated at 2.1, suggesting an "Outperform" status. This rating is based on a scale where 1 signifies Strong Buy and 5 indicates Sell.
Delving into proprietary metrics, GuruFocus estimates the GF Value for Alnylam Pharmaceuticals Inc (ALNY, Financial) at $436.84 within the next year. This suggests a potential upside of 72.26% from the current price of $253.60. The GF Value represents GuruFocus' assessment of the fair market value the stock should attain. This calculation is derived from the stock's historical trading multiples, past business performance, and projected future business performance. For further detailed insights, please refer to the Alnylam Pharmaceuticals Inc (ALNY) Summary page.
